Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition

Nature Communications

Volumn 6, Issue , 2015, Pages

  Goldman, Aaron ^a,b,c   Majumder, Biswanath ^d,e   Dhawan, Andrew ^f   Ravi, Sudharshan ^c   Goldman, David ^g   Kohandel, Mohammad ^h   Majumder, Pradip K ^d,e   Sengupta, Shiladitya ^a,b,c,i  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Center for Innovation   (India)

^e MSR Biotech Pvt Ltd   (India)

^f QUEEN S UNIVERSITY   (Canada)

^g Department of Applied Mathematics University of Waterloo ^*  (United States)

^h UNIVERSITY OF WATERLOO   (Canada)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; DASATINIB; DOCETAXEL; HEMATOPOIETIC CELL KINASE; HEMOPOIETIC CELL KINASE INHIBITOR; HERMES ANTIGEN; MEMBRANE LIPID; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; BRIDGED COMPOUND; LEUKOCYTE ANTIGEN; PROTEIN KINASE INHIBITOR; TAXANE; TAXOID;

ADAPTATION; APOPTOSIS; CANCER; CHEMOTHERAPY; DISEASE TREATMENT; DRUG; PHENOTYPIC PLASTICITY; TUMOR; VULNERABILITY; WOMENS HEALTH;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TARGETING; ENZYME ACTIVATION; EXPLANT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID RAFT; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CANCER STEM CELL; CARCINOGENESIS; CELL MEMBRANE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY; PHENOTYPE; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BRIDGED-RING COMPOUNDS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEMBRANE MICRODOMAINS; MICE, INBRED BALB C; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TAXOIDS; TIME FACTORS;

EID: 84923103818     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7139     Document Type: Article

References (48)

1. Cairns, J. Mutation selection and the natural history of cancer. Nature 255, 197-200 (1975).
2. Redmond, K. M., Wilson, T. R., Johnston, P. G. & Longley, D. B. Resistance mechanisms to cancer chemotherapy. Front. Biosci. 13, 5138-5154 (2008).
3. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
4. Berrieman, H. K., Lind, M. J. & Cawkwell, L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 5, 158-164 (2004).
5. Talpaz, M. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99, 1928-1937 (2002).
6. Cara, S. & Tannock, I. F. Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance. Ann. Oncol. 12, 23-27 (2001).
7. Dawson, C. C., Intapa, C. & Jabra-Rizk, M. A. "Persisters": Survival at the cellular level. PLoS. Pathog. 7, e1002121 (2011).
8. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
9. Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: A looking glass for cancer? Nat. Rev. Cancer 12, 323-334 (2012).
10. Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644 (2011).
11. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA. Cancer J. Clin. 64, 9-29 (2014).
12. Giordano, S. H., Lin, Y. L., Kuo, Y. F., Hortobagyi, G. N. & Goodwin, J. S. Decline in the use of anthracyclines for breast cancer. J. Clin. Oncol. 30, 2232-2239 (2012).
13. Sengupta, S. et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568-572 (2005).
14. Lee, M. J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
15. Ellis, L. M. & Fidler, I. J. Finding the tumor copycat. Therapy fails, patients don't. Nat. Med. 16, 974-975 (2010).
16. Majumder, B. et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumor heterogeneity. Nat. Commun. (doi:10.1038/ncomms7169).
17. Tunggal, J. K., Cowan, D. S., Shaikh, H. & Tannock, I. F. Penetration of anticancer drugs through solid tissue: A factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer. Res. 5, 1583-1586 (1999).
18. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
19. Shipitsin, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (2007).
20. Pegram, M. D. et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer. Inst. 96, 739-749 (2004).
21. Nelli, F. et al. Gemcitabine and carboplatin for pretreated metastatic breast cancer: The predictive value of immunohistochemically defined subtypes. Int. J. Clin. Oncol. 18, 343-349 (2013).
22. Bouchet, B. P. & Galmarini, C. M. Cabazitaxel, a new taxane with favorable properties. Drugs Today (Barc) 46, 735-742 (2010).
23. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659 (2009).
24. Swanton, C. et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512 (2007).
25. Fox, D. T. & Duronio, R. J. Endoreplication and polyploidy: Insights into development and disease. Development 140, 3-12 (2013).
26. Saito, Y. et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci. Transl. Med. 5, 181ra152 (2013).
27. Sen, B. & Johnson, F. M. Regulation of SRC family kinases in human cancers. J. Signal Transduct. 2011, 865819 (2011).
28. Bretz, N. et al. CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin. Exp. Metastasis 29, 27-38 (2012).
29. Su, N. et al. Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer. Mol. Cancer 11, 43 (2012).
30. Moon, K. C. et al. Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res. 25, 4631-4637 (2005).
31. Yoo, S. H. et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42, 195-202 (2003).
32. Baumann, P. et al. CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell. Mol. Life. Sci. 69, 435-448 (2012).
33. Lee, J. L., Wang, M. J., Sudhir, P. R. & Chen, J. Y. CD44 engagement promotes matrix-derived survival through the CD44-SRC-integrin axis in lipid rafts. Mol. Cell. Biol. 28, 5710-5723 (2008).
34. Qayyum, T. et al. The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. Br. J. Cancer 106, 1187-1195 (2012).
35. Schlegel, A., Wang, C., Katzenellenbogen, B. S., Pestell, R. G. & Lisanti, M. P. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J. Biol. Chem. 274, 33551-33556 (1999).
36. Paliwal, P., Radha, V. & Swarup, G. Regulation of p73 by Hck through kinasedependent and independent mechanisms. BMC Mol. Biol. 8, 45 (2007).
37. Herold, C. I. et al. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin. Cancer Res. 17, 6061-6070 (2011).
38. Finn, R. S. et al. Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study. Clin. Cancer Res. 17, 6905-6913 (2011).
39. Araujo, J. C. et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 118, 63-71 (2012).
40. Fillmore, C. M. & Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25 (2008).
41. Kristiansen, G. et al. CD24 expression is a new prognostic marker in breast cancer. Clin. Cancer Res. 9, 4906-4913 (2003).
42. Pisco, A. O. et al. Non-Darwinian dynamics in therapy-induced cancer drug resistance. Nat. Commun. 4, 2467 (2013).
43. Cooper, J. A., Gould, K. L., Cartwright, C. A. & Hunter, T. Tyr527 is phosphorylated in pp60c-src: Implications for regulation. Science 231, 1431-1434 (1986).
44. Rao, X. et al. CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene 32, 4519-4528 (2013).
45. Ramadan, S. et al. p73 induces apoptosis by different mechanisms. Biochem. Biophys. Res. Commun. 331, 713-717 (2005).
46. Million, K. et al. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells. Int. J. Oncol. 29, 147-154 (2006).
47. von Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 15, 747-756 (2014).
48. Mehrara, E., Forssell-Aronsson, E., Ahlman, H. & Bernhardt, P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer. Res. 67, 3970-3975 (2007).